



GIG  
CYMRU  
NHS  
WALES

Bwrdd Iechyd Prifysgol  
Bae Abertawe  
Swansea Bay University  
Health Board

Cadeirydd/Chair: **Emma Woollett**  
Prif Weithredwr/Chief Executive: **Mark Hackett**

**gofalu am ein gilydd, cydweithio, gwella bob amser**  
**caring for each other, working together, always improving**

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 23<sup>rd</sup> February 2021  
Ein Cyf / Our Ref: 21-B-007

01639 648363

FOIA.Requests@wales.nhs.uk

[REDACTED]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

Dear [REDACTED]

I refer to your Freedom of Information Act Request acknowledged by ourselves on 4<sup>th</sup> February 2021. Your request sought information relating to cancer treatments.

Please note that we have provided the information over the period 01.10.20 to 31.12.20.

**1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?**

42 patients received first definitive treatment for Melanoma in the requested period, 11 of these were BRAF+.

**2. In the past 3 months, how many melanoma patients (any stage) were treated with the following:**

- Cobimetinib - 0
- Dabrafenib - <5\*
- Dabrafenib AND Trametinib - 25
- Encorafenib AND Binimetinib - 6
- Ipilimumab - 0
- Ipilimumab AND Nivolumab - <5\*
- Nivolumab - 10
- Pembrolizumab - 10
- Trametinib - 0
- Vemurafenib - <5\*
- Vemurafenib AND Cobimetinib - 0
- Other active systemic anti-cancer therapy - 0



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe  
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- Palliative care only - To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY:**

- Ipilimumab - 0
- Ipilimumab AND Nivolumab - <5\*
- Nivolumab - 9
- Pembrolizumab - <5\*
- Any other therapies - 22

**4. In the past 3 months how many patients were treated with the following for breast cancer?**

- Abemaciclib + Anastrozole/Exemestane/Letrozole - Unable to split Abemaciclib patients – total of 14 patients for all combinations
- Abemaciclib + Fulvestrant - See above
- Alpelisib + Fulvestrant - 0
- Atezolizumab - 0
- Bevacizumab - 0
- Eribulin - <5\*
- Everolimus + Exemestane - <5\* patients on Everolimus – Exemestane not prescribed on our system so unable to provide information on combination
- Fulvestrant as a single agent - 20
- Gemcitabine + Paclitaxel - 0
- Lapatinib - 0
- Neratinib - 0
- Olaparib - 0
- Palbociclib + Anastrozole/Exemestane/Letrozole - 33 patients on Palbociclib – aromatase inhibitors not prescribed on our system so unable to provide information on combination
- Palbociclib + Fulvestrant – See above
- Pertuzumab + Trastuzumab + Docetaxel - 13
- Ribociclib + Anastrozole/Exemestane/Letrozole - Unable to split Ribociclib patients – total of 6 patients for all combinations
- Ribociclib + Fulvestrant - See above
- Talazoparib - 0
- Trastuzumab + Paclitaxel - <5\*
- Trastuzumab as a single agent - 44
- Trastuzumab emtansine - 7
- Any other active systemic anti-cancer therapy - 88



\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

